Release Date: August 26, 2025
Expiration Date: August 26, 2026
Activity Overview
Targeted and immunological treatments are important in the standard of care for advanced biliary tract cancers (BTCs). However, pivotal trials have left many questions unanswered about the optimal use of these treatment approaches, and the field is continuing to explore novel targets to exploit. In this activity, expert faculty in the management of BTCs discuss recent data informing optimal treatment selection for patients with metastatic BTC.
Target Audience
This educational activity is directed toward US-based medical oncologists, gastrointestinal oncologists, advanced practice providers, nurses, and other health care providers who treat patients with GI cancers.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate immune-based treatment strategies for advanced hepatobiliary cancers and their applicability to diverse patient populations, including those with hepatic dysfunction or poor performance status.
Ghassan Abou-Alfa, MD, MBA
Professor of Medicine
Weill Cornell Medicine
Attending Physician
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Consultant: AbbVie, Alligator Bioscience, AstraZeneca, Autem Therapeutics, Berry Genomics, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Incyte, Ipsen, J-Pharma, Merck, Merus, Neogene Therapeutics, Novartis, Servier, Tango Therapeutics, Tempus, Vector Pharma, Yiviva; Grant/Research Support: Agenus, Arcus, AstraZeneca, BioNTech, Bristol Myers Squibb, Elicio Therapeutics, Genentech/Roche, Helsinn, Parker Institute, Pertzye, Puma, QED Therapeutics, Servier, Yiviva
Laura Williams Goff, MD, MSCI, MMHC, FASCO
Professor of Medicine
Division of Hematology-Oncology
Vanderbilt University Medical Center
Nashville, TN
Disclosures: Adviser, Consultant, Speaker, Honoraria Recipient: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Exelixis, Jazz Pharmaceuticals, Merck, QED, Relay Therapeutics; Grant/Research Funding: Agios, Aslan, Basilea, BeiGene, Bristol Myers Squibb, Merck
Arndt Vogel, MD, PhD
Professor of Medicine, University of Toronto
Longo Family Chair in Liver Cancer Research
Clinician Scientist
Division of Gastroenterology and Hepatology, Toronto General Hospital
Medical Oncology, Princess Margaret Cancer Centre
Toronto General Hospital Research Institute
Schwartz Reisman Liver Research Centre
Institute for Medical Science
Toronto, Canada
Disclosures: Adviser, Consultant, Speaker, Honoraria Recipient: AbbVie, AstraZeneca, Biologix, Boehringer Ingelheim, Bristol Myers Squibb, Cogent, Eisai, Elevar, Incyte, Ipsen, Janssen, Jazz Pharmaceuticals, Lilly, Medivir, MSD, Roche, Servier, Taiho, Terumo, Tyra, Zymeworks
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login HereAccreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.
Physician Education Resources is proud to partner with Cholangiocarcinoma Foundation (CCF).
